Abstract
Despite early antiviral treatment, herpes simples virus encephalitis (HSVE) still remains a life-threatening sporadic disease with high mortality and morbidity. In patients and in experimental disease, chronic progressive magnetic resonance imaging (MRI) abnormalities have been found even after antiviral therapy. Secondary autoimmune-mediated and not directly virus-mediated mechanisms might play a key role for the outcome of disease. This study aimed to evaluate a possible beneficial effect of a therapy of acyclovir and corticosteroids versus acyclovir only. In a mouse model of HSVE (intranasal inoculation with 105 pfu [plaque-forming units] of HSV-1 strain F), a long-term MRI study was realized. Cranial MRI was performed serially at days 2, 7, 14, 21, 60, and 180 in different therapy groups: 1, saline; 2, acyclovir; 3, acyclovir, subsequently methylprednisolone; 4, sham-infected with saline. Brain viral load peaked at day 7 to decline thereafter to a low baseline value. Viral load in group 1 was significantly higher than in animals with antiviral therapy. In group 4, no viral DNA was detectable. Viral load did not differ significantly between acyclovir and acyclovir/corticosteroid-treated groups, suggesting that the use of corticosteroids in addition to acyclovir does not increase viral burden. MRI findings in untreated and acyclovir-treated animals revealed chronic progressive changes. In contrast, there was a significant reduction of the severity of long-term MRI abnormalities in acyclovir/corticosteroid-treated animals. With respect to abnormal MRI findings, this study demonstrates a clear beneficial effect of an acyclovir and corticosteroid therapy without influencing brain viral load.
References
Anderson JR, Field HJ (1983). The distribution of herpes simplex type 1 antigen in mouse central nervous system after different routes of inoculation. J Neurol Sci 60: 181–195.
Ando Y, Kimura H, Miwata H, Kudo T, Shibata M, Morishima T (1993). Quantitative analysis of herpes simplex virus DNA in cerebrospinal fluid of children with herpes simplex encephalitis. J Med Virol 41: 170–173.
Aurelius E, Andersson B, Forsgren M, Skoldenberg B, Strannegard O (1994). Cytokines and other markers of intrathecal immune response in patients with herpes simplex encephalitis. J Infect Dis 170: 678–681.
Aurelius E, Forsgren M, Skoldenberg B, Strannegard O (1993). Persistent intrathecal immune activation in patients with herpes simplex encephalitis. J Infect Dis 168: 1248–1252.
Baringer JR, Klassen T, Grumm F (1976). Experimental herpes simplex virus encephalitis. Effect of corticosteroids and pyrimidine nucleoside. Arch Neurol 33: 442–446.
Barthez-Carpentier MA, Rozenberg F, Dussaix E, Lebon P, Goudeau A, Billard C, Tardieu M (1995). Relapse of herpes simplex encephalitis. J Child Neurol 10: 363–368.
Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, Jones T, Banati RB (2001). In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 124: 2014–2027.
Chan WL, Javanovic T, Lukic ML (1989). Infiltration of immune T cells in the brain of mice with herpes simplex virus-induced encephalitis. J Neuroimmunol 23: 195–201.
Darai G, Scholz J, Kurz W, Koch HG (1982). Intertypic super-infection of herpes simplex virus in vivo leads to reisolation of latent viruses with newly acquired lymphotropic properties. Dev Biol Stand 52: 67–80.
Demaerel P, Wilms G, Robberecht W, Johannik K, Van Hecke P, Carton H, Baert AL (1992). MRI of herpes simplex encephalitis. Neuroradiology 34: 490–493.
Dennett C, Klapper PE, Cleator GM (1996). Polymerase chain reaction in the investigation of “relapse” following herpes simplex encephalitis. J Med Virol 48: 129–132.
Dragoje S, Tolnay M, Dalquen P, Probst A (1995). Brain irradiation and antioedematous dexamethasone treatment—risk factors for herpes simplex encephalitis? Schweiz Arch Neurol Psychiatr 146: 277–280.
Ejercito PM, Kieff ED, Roizman B (1968). Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol 2: 357–364.
Esiri MM, Drummond CW, Morris CS (1995). Macrophages and microglia in HSV-1 infected mouse brain. J Neuroimmunol 62: 201–205.
Esiri MM, Kennedy PGE (1997). Viral diseases. In: Greenfield’s neuropathology. Graham DI, Lantos PL (eds). Edward Arnold: London, pp 3–63.
Gilbert DN, Moellering RC, Sande MA (2001). The Sanford guide to antimicrobial therapy 2001. Gilbert DN, Moellering RC, Sande MA (eds). Antimicrobial Therapy, Inc.: Hyde Park, pp 101–102.
Gold R, Buttgereit F, Toyka KV (2001). Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117: 1–8.
Haas J, Meyding-Lamade U, Fath A, Stingele K, Storch-Hagenlocher B, Wildemann B (1999). Acyclovir treatment of experimentally induced herpes simplex virus encephalitis: monitoring the changes in immunologic NO synthase expression and viral load within brain tissue of SJL mice. Neurosci Lett 264: 129–132.
Habel AH, Brown JK (1972). Dexamethasone in herpes-simplex encephalitis. Lancet 1: 695.
Hayden FG (2001). Antimicrobial agents: antiviral agents (nonretroviral). In: Goodman & Gilman’s the pharmacological basis of therapeutics. Hardman JG, Limbird LE (eds). McGraw-Hill: New York, pp 1313–1348.
Hisanaga K, Hosokawa M, Sato N, Mochizuki H, Itoyama Y, Iwasaki Y (1999). “Neuro-sweet disease”: benign recurrent encephalitis with neutrophilic dermatosis. Arch Neurol 5: 1010–1013.
Hudson SJ, Dix RD, Streilein JW (1991). Induction of encephalitis in SJL mice by intranasal infection with herpes simplex virus type 1: a possible model of herpes simplex encephalitis in humans. J Infect Dis 163: 720–727.
Ito Y, Kimura H, Yabuta Y, Ando Y, Murakami T, Shiomi M, Morishima T (2000). Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir. Clin Infect Dis 30: 185–187.
Jacobs DH (1999). Herpes simplex virus encephalitis following corticosteroids and cranial irradiation. Neurology 52: 1108–1109.
Johnson RT (1996). Acute encephalitis. Clin Infect Dis 23: 219–224; quiz 225-216.
Kapur N, Barker S, Burrows EH, Ellison D, Brice J, Illis LS, Scholey K, Colbourn C, Wilson B, Loates M (1994). Herpes simplex encephalitis: long-term magnetic resonance imaging and neuropsychological profile. J Neurol Neurosurg Psychiatry 57: 1334–1342.
Kimura H, Aso K, Kuzushima K, Hanada N, Shibata M, Morishima T (1992). Relapse of herpes simplex encephalitis in children. Pediatrics 89: 891–894.
Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Hanlon C, Dietzschold B (1993). In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci USA 90: 3024–3027.
Lahat E, Barr J, Barkai G, Paret G, Brand N, Barzilai A (1999). Long term neurological outcome of herpes encephalitis. Arch Dis Child 80: 69–71.
Lamade UM, Lamadé W, Hess T, Gosztonyi G, Kehm R, Sartor K, Hacke W (1996). A mouse model of herpes simplex virus encephalitis: diagnostic brain imaging by magnetic resonance imaging. In Vivo 10: 563–568.
Lellouch-Tubiana A, Fohlen M, Robain O, Rozenberg F (2000). Immunocytochemical characterization of long-term persistent immune activation in human brain after herpes simplex encephalitis. Neuropathol Appl Neurobiol 26: 285–294.
Longson M, Beswick TS (1971). Dexamethasone treatment in herpes-simplex encephalitis. Lancet 1: 749–750.
Longson M, Juel-Jensen BE, Liversedge LA (1975). Systemic corticosteroids in treatment of herpes simplex encephalitis. BMJ 4: 578.
McFarland DJ, Hotchin J (1983). Host genetics and the behavioral sequelae to herpes encephalitis in mice. Physiol Behav 30: 881–884.
McFarland DJ, Sikora E, Hotchin J (1986). The production of focal herpes encephalitis in mice by stereotaxic inoculation of virus. Anatomical and behavioral effects. J Neurol Sci 72: 307–318.
McGrath N, Anderson NE, Croxson MC, Powell KF (1997). Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J Neurol Neurosurg Psychiatry 63: 321–326.
Meyding-Lamadé U, Haas J, Lamadé W, Stingele K, Kehm R, Fath A, Heinrich K, Storch Hagenlocher B, Wildemann B (1998a). Herpes simplex virus encephalitis: long-term comparative study of viral load and the expression of immunologic nitric oxide synthase in mouse brain tissue. Neurosci Lett 244: 9–12.
Meyding-Lamadé U, Lamadé W, Kehm R, Knopf KW, Hess T, Gosztonyi G, Degen O, Hacke W (1998b). Herpes simplex virus encephalitis: cranial magnetic resonance imaging and neuropathology in a mouse model. Neurosci Lett 248: 13–16.
Meyding-Lamadé U, Lamadé W, Kehm R, Oberlinner C, Fath A, Wildemann B, Haas J, Hacke W (1999a). Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load—an experimental mouse study. Eur J Neurol 6: 531–538.
Meyding-Lamade UK, Lamadé WR, Wildemann BT, Sartor K, Hacke W (1999b). Herpes simplex virus encephalitis: chronic progressive cerebral magnetic resonance imaging abnormalities in patients despite good clinical recovery. Clin Infect Dis 28: 148–149.
Meyding-Lamade U, Seyfer S, Haas J, Dvorak F, Kehm R, Lamade W, Hacke W, Wildemann B (2002). Experimental herpes simplex virus encephalitis: inhibition of the expression of inducible nitric oxide synthase in mouse brain tissue. Neurosci Lett 318: 21–24.
Molloy S, Allcutt D, Brennan P, Farrell MA, Perryman R, Brett FM (2000). Herpes simplex encephalitis occurring after chemotherapy, surgery, and stereotactic radiotherapy for medulloblastoma. Arch Pathol Lab Med 124: 1809–1812.
Nahmias AJ, Whitley RJ, Visintine AN, Takei Y, Alford CA Jr (1982). Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis 145: 829–836.
Paillard C, Vanhulle C, Devaux AM, Ensel P, Monroc-Morval M, Blanc T (1999). [Recurrence of herpes simplex encephalitis.] Arch Pediatr 6: 1081–1085.
Pike MG, Kennedy CR, Neville BG, Levin M (1991). Herpes simplex encephalitis with relapse. Arch Dis Child 66: 1242–1244.
Plantinga EG, Vanneste JA (2001). Mild herpes simplex encephalitis worsening despite acyclovir treatment. JNeurol 248: 237–238.
Rau P, Heiland S, Sellner J, Sartor K, Hacke W, Meyding-Lamadé U (2002). Experimental herpes simplex virus encephalitis: sequential diffusion-weighted magnetic resonance imaging. J Neurol 249 (Suppl 1): 168.
Sartor K (1991). Viral infections. In: MR imaging of the skull and brain. Sartor K (ed). Springer: Berlin, Heidelberg, New York, pp 645–648.
Schiff D, Rosenblum MK (1998). Herpes simplex encephalitis (HSE) and the immunocompromised: a clinical and autopsy study of HSE in the settings of cancer and human immunodeficiency virus-type 1 infection. Hum Pathol 29: 215–222.
Schimmer BP, Parker KL (2001). Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman & Gilmans The pharmacological basis of therapeutics. Hardman JG, Limbird LE (eds). McGraw-Hill: New York, pp 1649–1778.
Skoldenberg B (1991). Herpes simplex encephalitis. Scand J Infect Dis Suppl 80: 40–46.
Skoldenberg B, Forsgren M, Alestig K, Bergstrom T, Burman L, Dahlqvist E, Forkman A, Fryden A, Lovgren K, Norlin K, et al (1984). Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 2: 707–711.
Smith CC (1975). Diseases of the central nervous system. Meningitis and encephalitis. BMJ 4: 335–337.
Sobel RA, Collins AB, Colvin RB, Bhan AK (1986). The in situ cellular immune response in acute herpes simplex encephalitis. Am J Pathol 125: 332–338.
Soto-Hernandez JL (2000). Follow-up in herpes simplex virus encephalitis. Clin Infect Dis 31: 206–207.
Steiner I, Kennedy PG (1995). Herpes simplex virus latent infection in the nervous system. J NeuroVirol 1: 19–29.
Straub J, Chofflon M, Delavelle J (1997). Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 49: 1145–1147.
Thompson KA, Blessing WW, Wesselingh SL (2000). Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J NeuroVirol 6: 25–32.
Tyler KL, Tedder DG, Yamamoto LJ, Klapper JA, Ashley R, Lichtenstein KA, Levin MJ (1995). Recurrent brain-stem encephalitis associated with herpes simplex virus type 1 DNA in cerebrospinal fluid. Neurology 45: 2246–2250.
Upton AR, Barwick DD, Foster JB (1971a). Dexamethasone treatment in herpes-simplex encephalitis. Lancet 1: 290–291.
Upton AR, Foster JB, Barwick DD (1971b). Dexamethasone treatment in herpes-simplex encephalitis. Lancet 1: 861.
VanLandingham KE, Marsteller HB, Ross GW, Hayden FG (1988). Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA 259: 1051–1053.
Whitley RJ (1991). Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes. Drugs 42: 406–427.
Whitley RJ (1997). Herpes simplex virus. In: Infections of the central nervous system. Scheld WM, Whitley RJ, Durack DT (eds). Lippincott-Raven Publishers: Philadelphia, New York, pp 73–90.
Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong SJ (1986). Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314: 144–149.
Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamade U, Steinvorth S, Hacke W, Haas J (1997). Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology 4: 1341–1346.
Yamamoto K, Chiba HO, Ishitobi M, Nakagawa H, Ogawa T, Ishii K (1997). Acute encephalopathy with bilateral striatal necrosis: favourable response to corticosteroid therapy. Eur J Paediatr Neurol 1: 41–45.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meyding-Lamadé, U.K., Oberlinner, C., Rau, P.R. et al. Experimental herpes simplex virus encephalitis: A combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. Journal of NeuroVirology 9, 118–125 (2003). https://doi.org/10.1080/13550280390173373
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280390173373